{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:08:03Z","timestamp":1791983283069,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prnil.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:04:09Z","timestamp":1752613449000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-027X","authenticated-orcid":false,"given":"Rocio","family":"Roldan-Testillano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-2645","authenticated-orcid":false,"given":"Lara","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5720-8991","authenticated-orcid":false,"given":"Claudia","family":"Covarrubias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0339-457X","authenticated-orcid":false,"given":"Francisco","family":"Durazo-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Arezki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Anidjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sanchez-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prnil.2025.07.002_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.prnil.2025.07.002_bib2","article-title":"Innovations and emerging trends in prostate cancer management: a literature review","volume":"16","author":"Ibraheem","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.prnil.2025.07.002_bib3","doi-asserted-by":"crossref","first-page":"712.e1","DOI":"10.1016\/j.clgc.2023.04.013","article-title":"An update on focal therapy for prostate cancer","volume":"21","author":"Ayerra Perez","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.prnil.2025.07.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/iju.iju_166_21","article-title":"Focal therapy for localized prostate cancer\u2014current status","volume":"38","author":"Atluri","year":"2022","journal-title":"Indian J Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","article-title":"Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018","volume":"74","author":"Van der Poel","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib6","article-title":"Identifying the best candidate for focal therapy: a comprehensive review","author":"Ghoreifi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prnil.2025.07.002_bib7","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2013.05.048","article-title":"The role of focal therapy in the management of localised prostate cancer: a systematic review","volume":"66","author":"Valerio","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib8","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-2337","article-title":"Narrative review\u2014focal therapy: are we ready to change the prostate cancer treatment paradigm?","volume":"11","author":"Williams","year":"2023","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.prnil.2025.07.002_bib9","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.21037\/tcr-23-2406","article-title":"A narrative clinical trials review in the realm of focal therapy for localized prostate cancer","volume":"13","author":"Lazarovich","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"5","key":"10.1016\/j.prnil.2025.07.002_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.prnil.2025.07.002_bib11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ijc.34743","article-title":"Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis","volume":"154","author":"Lehto","year":"2023","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.prnil.2025.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMcibr0905562","article-title":"The index lesion and the origin of prostate cancer","volume":"361","author":"Ahmed","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.prnil.2025.07.002_bib13","first-page":"873","article-title":"Focal therapy for prostate cancer \u2013 index lesion treatment vs. hemiablation. A matter of definition","volume":"45","author":"Stabile","year":"2019","journal-title":"IBJU"},{"issue":"48","key":"10.1016\/j.prnil.2025.07.002_bib14","article-title":"Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena","volume":"15","author":"Khoo","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.purol.2020.09.012","article-title":"What to expect from a non-suspicious prostate MRI? A review","volume":"30","author":"Fiard","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib16","first-page":"85","article-title":"Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible prostate cancers: a matched-pair analysis","author":"Oderda","year":"2025","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.prnil.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bju.16669","article-title":"Refining partial gland ablation for localised prostate cancer: the FALCON project","volume":"135","author":"Rodriguez-Sanchez","year":"2025","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.prnil.2025.07.002_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.euf.2021.04.008","article-title":"Long-term outcomes of focal cryotherapy for low- to intermediate-risk prostate cancer: results and matched pair analysis with active surveillance","volume":"8","author":"Marra","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.prnil.2025.07.002_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(13)61950-9","article-title":"Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial","volume":"383","author":"Vaidya","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prnil.2025.07.002_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.prnil.2025.07.002_bib22","first-page":"343","article-title":"Effect of focal vs extended irreversible electroporation for the ablation of localized low- or intermediate-risk prostate cancer on early oncological control A randomized clinical trial","volume":"158","author":"Zhang","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.prnil.2025.07.002_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prnil.2025.07.002_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"Eau - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer 2024","author":"Cornford","year":"2024","journal-title":"Eur Assoc Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.eururo.2015.12.015","article-title":"Focal Therapy for Prostate Cancer: An \u2018\u2018A` la Carte\u2019\u2019 Approach","volume":"69","author":"Sivaraman","year":"2016","journal-title":"Euroepan Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib27","article-title":"3RD WUOF\/SIU icud on localized prostate cancer","author":"Klotz","year":"2024","journal-title":"COMMITTEE 13 Focal Therapy\u2014Principles and Outcomes"},{"key":"10.1016\/j.prnil.2025.07.002_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JU.0000000000001787","article-title":"Association between lesion location and oncologic outcomes after focal therapy for localized prostate cancer using either high intensity focused ultrasound or cryotherapy","volume":"206","author":"Stabile","year":"2021","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.prnil.2025.07.002_bib29","article-title":"Focal therapy for prostate cancer: recent advances and insights","volume":"32","author":"Lasorsa","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3348\/kjr.2008.9.4.291","article-title":"High-intensity focused ultrasound therapy: an overview for radiologists","volume":"9","author":"Kim","year":"2008","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.prnil.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.diii.2018.03.001","article-title":"High intensity focused ultrasound: the fundamentals, clinical applications and research trends","volume":"99","author":"Shehata Elhelf","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.prnil.2025.07.002_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12262-009-0091-7","article-title":"Advances and future directions in management of prostate cancer","volume":"71","author":"Krane","year":"2009","journal-title":"Indian J Surg"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamcollsurg.2007.03.007","article-title":"Cryosurgery for tumors","volume":"205","author":"Gage","year":"2007","journal-title":"Am Coll Surg"},{"key":"10.1016\/j.prnil.2025.07.002_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","year":"2017","journal-title":"Euroepan Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib35","first-page":"12","article-title":"Photodynamic therapy for prostate cancer: recent advances, challenges and opportunities","author":"Xue","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.prnil.2025.07.002_bib36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.21037\/tau.2019.09.12","article-title":"Targeting the cancer lesion, not the whole prostate","volume":"9","author":"Bedi","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.prnil.2025.07.002_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jvir.2018.09.016","article-title":"Focal laser ablation of prostate cancer: results in 120 patients with low to intermediate risk disease","volume":"30","author":"Walser","year":"2019","journal-title":"J Vasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10439-005-8981-8","article-title":"Tissue ablation with irreversible electroporation","volume":"33","author":"Davalos","year":"2005","journal-title":"Ann Biomed Eng"},{"issue":"4","key":"10.1016\/j.prnil.2025.07.002_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215093","article-title":"Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments","volume":"14","author":"Guenther","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.prnil.2025.07.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000502553","article-title":"Oncological outcome and value of postoperative magnetic resonance imaging after focal high-intensity focused ultrasound therapy for prostate cancer","volume":"103","author":"Rosenhammer","year":"2019","journal-title":"Int Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-018-2363-y","article-title":"et al.Surveillance after prostate focal therapy","volume":"37","author":"Tay","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib43","first-page":"59","article-title":"Extraprostatic needle canal recurrence of localized prostate cancer after Nanoknife electroporation ablation diagnosed with PSMA PET\/MRI","author":"Jochumsen","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.prnil.2025.07.002_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41391-023-00699-7","article-title":"Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review","volume":"27","author":"Nicoletti","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib45","first-page":"263","article-title":"Available evidence on HIFU for focal treatment of prostate cancer: a systematic review","volume":"48","author":"Bakavicius","year":"2022","journal-title":"IBJU"},{"key":"10.1016\/j.prnil.2025.07.002_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2023.01.024","article-title":"Real-world comparative safety and effectiveness of irreversible electroporation and high-intensity focused ultrasound for prostate cancer AblationTagedEnd","volume":"174","author":"Cribbs","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.prnil.2025.07.002_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 Years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Euroepan Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.02.003","article-title":"Outcomes of focal therapy for localized prostate cancer: a systematic review and meta-analysis of prospective studies","author":"\u015alusarczyk","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib49","article-title":"Established focal therapy\u2014HIFU, IRE, or cryotherapy\u2014where are we now?\u2014a systematic review and meta-analysis","author":"Tay","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Supplement 4","key":"10.1016\/j.prnil.2025.07.002_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bju.15947","article-title":"Salvage irreversible electroporation for radio-recurrent prostate cancer \u2013 the prospective FIRE trial","volume":"131","author":"Blazevski","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.07.002_bib51","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.urolonc.2024.08.011","article-title":"Salvage local treatment for recurrent prostate cancer after focal therapy: a systematic review and meta-analysis","volume":"42","author":"Takemura","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prnil.2025.07.002_bib52","unstructured":"Clinicaltrials.gov [Internet]. Comparative health research outcomes of NOvel surgery in prostate cancer (CHRONOS). Disponible en: https:\/\/clinicaltrials.gov\/search?cond=NCT04049747."},{"key":"10.1016\/j.prnil.2025.07.002_bib53","series-title":"EvaluatioN of HIFU hemiablation and short term AndrogeN deprivation therapy combination to enhance prostate cancer control (ENHANCE)","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib54","series-title":"Effectiveness of focal therapy in men with prostate cancer (ENFORCE)","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib55","series-title":"Additional treatments to the local tumour for metastatic prostate cancer: assessment of novel treatment algorithms (ATLANTA)","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib56","series-title":"Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA). Disponible en","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib57","series-title":"Cost-utility of Focal HIFU vs Prostatectomy (EMERHIT). Disponible en","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib58","series-title":"A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer (CAPTAIN). Disponible en","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib59","series-title":"WATER IV prostate cancer","year":"2025"},{"key":"10.1016\/j.prnil.2025.07.002_bib60","series-title":"A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer. Disponible en","year":"2025"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/end.2022.0452","article-title":"Transurethral vapor ablation in patient s with intermediate-risk localized prostate cancer","volume":"37","author":"Dixon","year":"2023","journal-title":"J Endourol"},{"key":"10.1016\/j.prnil.2025.07.002_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euros.2022.10.004","article-title":"Safety and feasibility of transperineal targeted microwave ablation for low- to intermediate-risk prostate cancer","volume":"46","author":"Oderda","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.prnil.2025.07.002_bib63","doi-asserted-by":"crossref","unstructured":"Canfield SE, George AK, Jue JS, Lewis SC, Davenport MS, Tammisetti VS, et al. A multi-institutional study of magnetic resonance\/ultrasound FusioneGuided nanoparticle-directed focal therapy for prostate ablation. J Urol. 212:862\u2013872.","DOI":"10.1097\/JU.0000000000004222"},{"key":"10.1016\/j.prnil.2025.07.002_bib64","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000001362","article-title":"Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer","volume":"205","author":"Klotz","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.prnil.2025.07.002_bib65","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/13696998.2023.2251849","article-title":"Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a costeffectiveness analysis","volume":"26","author":"Reddy","year":"2023","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bju.16746","article-title":"Perioperative complications of focal therapy for prostate cancer: results from the German Nationwide inpatient Data (GRAND) study","volume":"136","author":"Pyrgidis","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.07.002_bib67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00345-018-2395-3","article-title":"Update on the ICUD-SIU consultation on multi-parametric magnetic resonance imaging in localised prostate cancer","volume":"37","author":"Barret","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2214\/AJR.16.17629","article-title":"Validation of prostate imaging reporting and data system version 2 using an MRI-ultrasound fusion biopsy in prostate cancer diagnosis","volume":"209","author":"Kim","year":"2017","journal-title":"Am Roentgen Ray Soc"},{"issue":"1","key":"10.1016\/j.prnil.2025.07.002_bib69","article-title":"PI-RADS v2.1: what has changed and how to report","volume":"25","author":"Scott","year":"2021","journal-title":"SA J Radiol"},{"key":"10.1016\/j.prnil.2025.07.002_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.07.002_bib71","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s11845-024-03771-w","article-title":"Precision in prostate cancer detection: integrating prostate-specific antigen density (PSAD) and the Prostate Imaging Reporting and Data System (PI-RADS) to provide additional risk stratification for a more accurate diagnostic decision","volume":"193","author":"Hrub\u00e1","year":"2024","journal-title":"Ir J Med Sci"},{"issue":"1158","key":"10.1016\/j.prnil.2025.07.002_bib72","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/bjr\/tqae080","article-title":"Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate","volume":"97","author":"Hrub\u00e1","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prnil.2025.07.002_bib73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted prostate biopsy: Umbra, penumbra, and value of perilesional sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Euroepan Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2022.07.006","article-title":"An magnetic resonance imaging\u2013directed targeted-plusperilesional biopsy approach for prostate cancer diagnosis: \u2018\u2018Less is more","volume":"43","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"67","key":"10.1016\/j.prnil.2025.07.002_bib75","doi-asserted-by":"crossref","first-page":"111073","DOI":"10.18632\/oncotarget.22441","article-title":"Diagnostic performance of 68Gallium-PSMA-11 PET\/CT to detect significant prostate cancer and comparison with 18FEC PET\/CT","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prnil.2025.07.002_bib76","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.prnil.2025.07.002_bib77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MOU.0000000000000986","article-title":"The role of novel imaging in prostate cancer focal therapy: treatment and follow-up","volume":"32","author":"Rothberg","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib79","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Euroepan Urol"},{"key":"10.1016\/j.prnil.2025.07.002_bib80","first-page":"1","volume":"116","author":"Pepe","year":"2024","journal-title":"Advances in radiology and pathology of prostate cancer: a review for the pathologist. Pathologica"},{"key":"10.1016\/j.prnil.2025.07.002_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041280","article-title":"Micro-ultrasound: current role in prostate cancer diagnosis and future possibilities","volume":"15","author":"Basso Dias","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2015.12.093","article-title":"Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification","volume":"196","author":"Ghai","year":"2016","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.prnil.2025.07.002_bib83","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis. The OPTIMUM randomized clinical trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.prnil.2025.07.002_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.456","article-title":"Focal therapy of prostate cancer: use of artificial intelligence to define tumour volume and predict treatment outcomes","volume":"6","author":"Brisbane","year":"2024","journal-title":"BJUI Compass"},{"issue":"7","key":"10.1016\/j.prnil.2025.07.002_bib85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2025.07.002_bib86","first-page":"87","article-title":"Multimodality focal therapy for prostate cancer: outcome of the a la carte approach in clinical practice","volume":"13","author":"Yee","year":"2025","journal-title":"Prostate Int"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:15:52Z","timestamp":1773843352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2287888225000637"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.07.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}